Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$27.90 USD

27.90
8,386,598

-0.81 (-2.82%)

Updated Aug 16, 2024 10:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer (PFE) Nimenrix Vaccine's Label Expanded in the EU

Pfizer Inc. (PFE) announced that the European Commission has approved an expanded indication for its meningococcal vaccine, Nimenrix.

    Allergan to Buy LifeCell to Boost Regenerative Medicine Suite

    Allergan plc (AGN) announced that it has signed a definitive agreement to acquire LifeCell, the regenerative medicine unit of Texas-based privately held company Acelity for $2.9 billion in cash.

      Merck Keytruda Gets CHMP Nod for First-Line Lung Cancer

      Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy, Keytruda, was rendered a positive opinion in the EU for the first-line treatment of metastatic lung cancer.

        Pfizer Chantix Label Warning Lifted in U.S.; to Add New Data

        Pfizer, Inc. (PFE) announced that the FDA has lifted a boxed warning about neuropsychiatric side effects from the label of its smoking cessation drug, Chantix.

          Arpita Dutt headshot

          Pharma Stock Roundup: Lilly Up on Guidance, Merck Awarded $2.54B in HCV Case

          Lilly (LLY) was among the biggest gainers among major pharma stocks last week with the company providing better-than-expected guidance for 2017.

            Swarup Gupta headshot

            Dow 30 Stock Roundup: Boeing, GE Raise Dividends; ExxonMobil Gets New CEO

            The Dow enjoyed a week of strong gains on rising expectations about the likely industry friendly policies of the Trump administration.

              Big Pharma Face Off: Is Merck More Attractive than J&J?

              Johnson & Johnson (JNJ) and Merck & Co. Inc. (MRK) are some of the better-performing large-cap pharma stocks

                Pfizer: FDA Approves Eczema Ointment; Xtandi Fails Study

                Pfizer, Inc. (PFE) announced that it received FDA approval for crisaborole topical ointment to treat mild-to-moderate eczema, or atopic dermatitis, in patients two years and older. The ointment will be sold under the brand name Eucrisa.

                  Will Buyback ETFs Gain Big on Overseas Cash Repatriation?

                  With Donald Trump winning the U.S. elections, a plethora of buybacks are expected to hit the market.

                    J&J (JNJ) Ends Deal Talks with Actelion: Will Sanofi Gain?

                    On Tuesday, Johnson & Johnson (JNJ) announced that it has ended talks regarding a possible transaction with Swiss biotechnology company, Actelion Ltd. (ALIOF), reportedly for a disagreement over the purchase price.

                      Lilly/AstraZeneca Expand Alzheimer Disease Collaboration

                      Eli Lilly and Company (LLY) and AstraZeneca plc (AZN) expanded their existing collaboration to develop the second treatment for Alzheimer's disease, MEDI1814

                        Pfizer (PFE) Fined for Price Hike of Anti-Epilepsy Drug in UK

                        Pfizer (PFE) fined for hiking price of an anti-epilepsy drug by up to 2,600% by the Competition and Markets Authority of the UK.

                          Arpita Dutt headshot

                          Should Biotech Investors Worry About Donald Trump?

                          It looks like biotech investors may have heaved a sigh of relief a bit too early when Presidential election results were announced last month.

                            Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study

                            Novartis (NVS) announced results from the phase III ASCEND-4 study on Zykadia, for the treatment of patients with advanced ALK+ NSCLC.

                              Pfizer Leukemia Drug Meets Primary Endpoint in Phase III

                              Pfizer Inc. (PFE) and partner Avillion LLP announced that a phase III study (BFORE) evaluating its marketed drug Bosulif in the first-line setting met the primary endpoint

                                Pfizer (PFE) Presents Favorable Data on Leukemia Candidate

                                Pfizer Inc. (PFE) announced new positive data from a randomized phase II study on its investigational candidate glasdegib (PF-04449913) for the first-line treatment of patients with acute myeloid leukemia (AML).

                                  Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma

                                  Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.

                                    Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug

                                    Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from epilepsy with partial-onset seizures.

                                      Tirthankar Chakraborty headshot

                                      5 Top Performing S&P 500 Stocks of November

                                      President-elect Donald Trump has proposed a raft of fiscal-stimulus measures, which has pushed the S&P 500 to almost an all-time high in November

                                        Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study

                                        Pfizer, Inc. (PFE) recently announced that its experimental biosimilar of Roche Holding AG's (RHHBY) breast cancer drug - Herceptin - has reached the primary endpoint in a pivotal study.

                                          ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.

                                          ARIAD Pharmaceuticals, Inc. (ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on accelerated approval in Dec 2012.

                                            Pfizer/Merck KGaA: Priority Review for Cancer Drug Avelumab

                                            Pfizer, Inc. (PFE) and German partner Merck KGaA (MKGAF) announced that the Biologics License Application for avelumab, has been accepted for priority review by the FDA.

                                              J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance

                                              Johnson & Johnson's (JNJ) share price is up 9.5% in the year-to-date period. This compares favorably with the 8.0% fall for the Zacks classified Large-Cap Pharma industry.

                                                The Zacks Analyst Blog Highlights: Pfizer, Microsoft, Priceline, Expedia and United Continental

                                                The Zacks Analyst Blog Highlights: Pfizer, Microsoft, Priceline, Expedia and United Continental

                                                  Stock Market News for November 21, 2016

                                                  Rising rate hike possibilities boosted the dollar to its best settlement in 13 years, which in turn dragged the benchmarks into the red on Friday.